Clinical and Molecular Prevalence of Lipodystrophy in an Unascertained Large Clinical Care Cohort
暂无分享,去创建一个
O. Gottesman | A. Shuldiner | H. Kirchner | M. Murray | J. Gromada | J. Overton | D. Carey | C. V. Van Hout | A. Baras | J. Leader | J. Staples | Wenzhen Ge | A. Yadav | J. Reid | C. Gonzaga‐Jauregui | J. Altarejos | Ryan D. Colonie | J. Reid | Steve Gao | C. V. van Hout | A. Shuldiner | Michael F. Murray | H. L. Kirchner | David J. Carey
[1] D. Savage,et al. What lipodystrophies teach us about the metabolic syndrome. , 2019, The Journal of clinical investigation.
[2] N. Patni,et al. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. , 2019, Pathology.
[3] B. Akıncı,et al. Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities , 2018, Current Diabetes Reports.
[4] Alexander E. Lopez,et al. Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes , 2017, bioRxiv.
[5] E. Chiquette,et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.
[6] Matthew S. Lebo,et al. A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort , 2017, bioRxiv.
[7] C. Vigouroux,et al. Clinical Utility Gene Card for: Familial partial lipodystrophy , 2017, European Journal of Human Genetics.
[8] Zhen Wang,et al. Clinical Features and Management of Non-HIV–Related Lipodystrophy in Children: A Systematic Review , 2017, The Journal of clinical endocrinology and metabolism.
[9] Marylyn D. Ritchie,et al. Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.
[10] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[11] Inês Barroso,et al. Prospective functional classification of all possible missense variants in PPARG , 2016, Nature Genetics.
[12] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[13] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[14] A. Garg. Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .
[15] S. O’Rahilly,et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. , 2011, The New England journal of medicine.
[16] A. K. Agarwal,et al. Lipodystrophies: disorders of adipose tissue biology. , 2009, Biochimica et biophysica acta.
[17] R. Hegele,et al. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. , 2007, The Journal of clinical endocrinology and metabolism.
[18] A. Garg,et al. Genetic disorders of adipose tissue development, differentiation, and death. , 2006, Annual review of genomics and human genetics.
[19] A. Garg,et al. Laminopathies: multisystem dystrophy syndromes. , 2006, Molecular genetics and metabolism.
[20] A. Garg. Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.
[21] Jimmy D Bell,et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. , 2003, Diabetes.
[22] J. Papp,et al. Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13 , 2001, Nature Genetics.
[23] R. Hegele,et al. LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration. , 2000, The Journal of clinical endocrinology and metabolism.
[24] R. Hegele,et al. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. , 2000, Genome research.
[25] M. Lovett,et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. , 2000, American journal of human genetics.
[26] S. Gregory,et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy , 2000, Nature Genetics.
[27] S. O’Rahilly,et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.
[28] A. Garg,et al. Lipodystrophy Syndromes. , 2016, Endocrinology and metabolism clinics of North America.
[29] A. Bowcock,et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.
[30] A. Bowcock,et al. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. , 2001, The Journal of clinical endocrinology and metabolism.
[31] R. Hegele,et al. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.